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Open access under CC BY-NC-ND license.BACKGROUND & AIMS: The mechanisms by which
Epstein–Barr virus (EBV) contributes to the development of
gastric cancer are unclear. We investigated EBV-associated
genomic and epigenomic variations in gastric cancer cells
and tumors. METHODS: We performed whole-genome, tran-
scriptome, and epigenome sequence analyses of a gastric
adenocarcinoma cell line (AGS cells), before and after EBV
infection. We then looked for alterations in gastric tumor
samples, with (n ¼ 34) or without (n ¼ 100) EBV infection,
collected from patients at the Prince of Wales Hospital, Chi-
nese University of Hong Kong (from 1998 through 2004), or
the First Afﬁliated Hospital of Sun Yat-sen University,
Guangzhou, China (from 1999 through 2006). RESULTS:
Transcriptome analysis showed that infected cells expressed
9 EBV genes previously detected in EBV-associated gastric
tumors and 71 EBV genes not previously reported in gastric
tumors. Ten viral genes that had not been reported previously
in gastric cancer but were expressed most highly in EBV-
infected cells also were expressed in primary EBV-positive
gastric tumors. Whole-genome sequence analysis identiﬁed
45 EBV-associated nonsynonymous mutations. These muta-
tions, in genes such as AKT2, CCNA1, MAP3K4, and TGFBR1,
were associated signiﬁcantly with EBV-positive gastric tumors,
compared with EBV-negative tumors. An activating mutation
in AKT2 was associated with reduced survival times of patients
with EBV-positive gastric cancer (P ¼ .006); this mutation was
found to dysregulate mitogen-activated protein kinase
signaling. Integrated epigenome and transcriptome analyses
identiﬁed 216 genes transcriptionally down-regulated by EBV-
associated hypermethylation; methylation of ACSS1, FAM3B,
IHH, and TRABD increased signiﬁcantly in EBV-positive tu-
mors. Overexpression of Indian hedgehog (IHH) and TraB
domain containing (TRABD) increased proliferation and colony
formation of gastric cancer cells, whereas knockdown of these
genes reduced these activities. We found 5 signaling pathways
(axon guidance, focal adhesion formation, interactions among
cytokines and receptors, mitogen-activated protein kinase
signaling, and actin cytoskeleton regulation) to be affected
commonly by EBV-associated genomic and epigenomic alter-
ations. CONCLUSIONS: By using genomic, transcriptome, and
epigenomic comparisons of EBV infected vs noninfected
gastric cancer cells and tumor samples, we identiﬁed alter-
ations in genes, gene expression, and methylation that affectdifferent signaling networks. These might be involved in EBV-
associated gastric carcinogenesis.Keywords: Genome Sequencing; Transcriptome; Methylation;
AKT2.
pstein–Barr virus (EBV) is a human herpes virusEthat infects more than 90% of the world population
before adolescence. This oncogenic virus has been identiﬁed
in epithelial malignancies including gastric cancer.1 EBV-
associated gastric cancer accounts for 8%–10% of all
gastric cancer cases and is estimated to occur in more than
90,000 patients annually.2 EBV-associated (EBV(þ)) gastric
cancer represents a distinct subtype of gastric cancer, with
unique clinicopathologic features as compared with EBV-
negative (EBV(-)) gastric cancer. However, the molecular
genetic changes that account for the malignant behavior of
EBV-associated gastric cancer remain largely unclear.
Clonal EBV is present in nearly all neoplastic cells and
thus suggests a causal role in gastric carcinogenesis. In
healthy individuals, EBV infection of gastric epithelial cells is
a rare event. Even if EBV infects gastric epithelial cells, EBV
usually is cytotoxic and induces cell death. However, once
triggered, EBV infection will evolve into a persistent latent
infection, which initiates progression into gastric cancer.
Previous studies on EBV-associated gastric cancer by us3
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methylation, which is a consequence of increased activity of
DNA methyltransferases caused by EBV gene expression
such as latent membrane protein 2A (LMP2A). Other studies
also have investigated host genetic abnormalities including
gene mutation,5 microsatellite instability,6 and cytogenetics7
in EBV-associated gastric cancer. These ﬁndings collectively
infer that EBV infection affects host cells at both epigenomic
and genomic levels during gastric carcinogenesis.
However, systematic and integrative analyses concerning
the impact of EBV on host cell alterations have not been per-
formed to date. The AGS–EBV cell model with stable EBV
infection has been applied successfully to study the effects of
EBV infection in gastric cancer by us3,8 and others.9,10 Suc-
cessful identiﬁcation of EBV-associated methylated genes in
gastric cancer using the AGS–EBV cell model highlights the
feasibility of studying EBV-associated aberrations in gastric
cancer using this cell model. The purpose of this study was to
systematically elucidate the molecular genetic characteristics
of EBV-associated gastric cancer by cataloguing the genomic
and epigenomic alterations detected by whole-genome se-
quencing, transcriptome sequencing, and epigenome analysis
in AGS–EBV cells as comparedwith the parental EBV-negative
AGS cells, with an emphasis on identifying EBV-associated
genomic/epigenomic events and aberrant molecular path-
ways. The identiﬁed important molecular abnormalities were
veriﬁed further in primary EBV(þ) gastric cancers.BA
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AGS–EBV Cell Model
The AGS–EBV cell model stably infected with a recombinant
EBV strain (added with a hygromycin-resistance gene for se-
lective maintenance of EBV-positive cells during culture) was a
gift from Dr Shannon C. Kenney (University of Wisconsin School
of Medicine and Public Health).3 The uninfected AGS cells, and
AGS cells stably transfected with the empty pRI-GFP/Hygro
vector producing hygromycin-resistance (AGS-hygro), were
used as controls in this study.Human Gastric Samples
Gastric cancer samples were collected in the Prince of
Wales Hospital, The Chinese University of Hong Kong from
1998 to 2004, and the First Afﬁliated Hospital of Sun Yat-sen
University in Guangzhou from 1999 to 2006. The presence of
EBV was determined by in situ hybridization analysis of EBV-
encoded small RNA, and quantitative polymerase chain reac-
tion (qPCR) examination of BamH1W and EBNA1 regions at the
DNA level as described previously.1 Gastric cancer samples
with positive results for both in situ hybridization and qPCR
examination were considered EBV-positive (n ¼ 34), whereas
those with negative results for both were considered EBV-
negative (n ¼ 100). Informed consent was provided by all
participants, and this study was approved by both the ethics
committee of the Chinese University of Hong Kong and the
Clinical Research Ethics Committee of Sun Yat-sen University.
Other details and additional experimental procedures are
provided in the Supplementary Materials and Methods.Results
EBV Copies and Viral Gene Expression in
AGS–EBV Shown by Whole Genome and
Transcriptome Sequencing
Whole-genome sequencing reads were mapped to both
the human reference genome (UCSC hg19) and the EBV
reference genome (NC_007605). Whole-genome sequencing
of the AGS–EBV and AGS cells showed a sequencing depth of
59-fold in AGS–EBV, and 42-fold in AGS for the human
genome. A total of 91.59% and 91.57% of the whole genome
region in AGS–EBV and AGS, respectively, were covered
with more than 10 reads. Moreover, an 897-fold sequencing
depth covering 91.38% of the whole EBV genome was ob-
tained in AGS–EBV cells only (Supplementary Figure 1A).
Therefore, approximately 15 EBV episomes in 1 AGS–EBV
cell could be inferred (897-fold EBV/59-fold human¼ 15.2),
consistent with the ﬁndings by others.11
In an attempt to uncover the EBV gene expression status
in gastric cancer cells, 154.09 Mb reads of the AGS–EBV
transcriptome were mapped to the EBV genome, with
sequencing reads distributed across the entire EBV genome
(Figure 1A). Visualization of transcriptome sequencing
coverage across the EBV genome showed an EBV tran-
scription proﬁle in AGS–EBV cells with active regions
similar to those identiﬁed in type I latency Burkitt’s lym-
phoma cells (Supplementary Figure 1B).12 Robust viral gene
expression was yielded in AGS–EBV cells, with a median
expression level of all genes being 255.4 reads per kilobase
per million (RPKM) (Figure 1B). Transcriptome analysis of
AGS–EBV identiﬁed the expression of 9 EBV genes (BARF0,
BARF1, BcLF1, BHRF1, BLLF1, BRLF1, BZLF1, EBNA1, and
LMP2A) previously detected in EBV(þ) gastric tumors, and
71 EBV genes not reported previously in gastric cancer. The
expression levels of these 71 genes are higher than that of
LMP2A (27.0 RPKM), which could be well validated by
reverse-transcription (RT)-PCR (Figure 1B and
Supplementary Tables 1 and 2).EBV Gene Expression Identiﬁed in AGS–EBV Is
Veriﬁed in EBV(þ) Gastric Cancer Cell Lines and
Primary Gastric Cancer Tissues
The top 11 EBV genes (BNLF2a, BNLF2b, BHRF1, BFRF1,
BFRF2, BFRF3, BKRF4, BMRF2, BKRF3, BMRF1, and BFRF1A)
were veriﬁed in AGS–EBV and 2 other EBV(þ) gastric can-
cer cell lines with natural EBV infection (SNU719 and
YCCEL1) by RT-PCR. The expression of all 11 genes was
detected in the 3 EBV(þ) gastric cancer cell lines, but not in
EBV(-) AGS cells (Figure 1B). Notably, BHRF1, a viral
oncogene detected in EBV(þ) gastric cancer,13,14 was the
third most highly transcribed EBV gene in AGS–EBV (5103.9
RPKM). The other 10 genes have not been examined pre-
viously in primary gastric cancer, including the DNA repli-
cation or repair enzyme BKRF3, capsid or tegument coding
genes (BFRF1, BFRF3, and BKRF4), the gene facilitating viral
attachment to cells (BMRF2), 2 uncharacterized EBV genes
(BFRF2 and BFRF1A), and 3 lytic genes (BNLF2a, BNLF2b,
and BMRF1). We performed immunoﬂuorescence
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early lytic gene BRLF1, and found that 2% of the AGS–EBV
cells were positive for BRLF1, which are entering the lytic
phase of EBV replication (Supplementary Figure 1C). The 10
EBV genes veriﬁed in AGS–EBV, SNU719, and YCCEL1 were
veriﬁed further in primary EBV(þ) gastric cancer tissues
with a positive detection rate between 7.7% and 46.2% by
RT-PCR (Figure 1C). Expression of EBV genes may
contribute to EBV-associated gastric carcinogenesis.BA
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Landscape Identiﬁed by Whole-Genome
Sequencing
We compared the whole genome sequences of AGS–EBV
and AGS to identify EBV-caused host genomic alterations,
including single-nucleotide variants (SNVs)/point muta-
tions, small insertions and deletions (indels), and structural
variations (SVs) (Supplementary Tables 3–8). A total of 139
EBV-associated SNVs covering 131 genes were identiﬁed to
be of interest, including 45 nonsynonymous SNVs (affecting
44 genes), and 94 SNVs located at important regulatory
regions (splice sites, 5- or 3-untranslated regions, and pro-
moter regions; affecting 87 genes). We also found 56 indels
covering 54 genes in AGS–EBV and 48 AGS–EBV–speciﬁc SV
events affecting 24 genes and other nongene regions.
Seven randomly selected SNVs in 6 genes (AKT2, CCNA1,
TGFBR1, ACVR1C, MAP3K4, and NRXN1) were well validated
in AGS–EBV, but not in AGS or AGS-hygro by PCR followed
by Sanger sequencing (Supplementary Figure 2A). Among
them, AKT2, the putative oncogene documented with
important functions in the cancer pathway of mitogen-
activated protein kinase (MAPK) signaling, harbors 2 EBV-
associated nonsynonymous SNVs. Two randomly selected
indels (FAM35A and ADAMTS12) and 4 randomly selected
SVs (GGT7-IRS1, KMD3A-KMD3A, SMAD5-STXBP5, and
NA-KDM3B) also were well validated in AGS–EBV by PCR
followed by Sanger sequencing, but were not detected in
AGS or AGS-hygro cells (Supplementary Figure 2B and C).Mutation Validation Reﬁned Mutated Genes in
Primary EBV(þ) Gastric Cancers
By comparing the 45 EBV-associated nonsynonymous
host SNVs/point mutations (covering 44 genes) (Figure 2A)
identiﬁed in AGS–EBV with the Catalogue of Somatic Muta-
tions in Cancer database, which collects somatic mutations in
human cancers, we found that all 44 genes had been recor-
ded, but none of the 45 mutation sites had been documented
(Supplementary Table 4), inferring the novelty and potential
importance of these mutations caused by EBV infection.=
Figure 1. EBV viral gene expression in AGS–EBV and in EBV
sequencing coverage across the EBV reference genome (NC
mapping reads to each location of the EBV genome. The upper
the EBV genes at each site are annotated at the lower panel u
Cambridge, MA). (B) RPKM values for EBV gene expression lev
AGS and 3 EBV-positive gastric cancer cells (AGS-EBV, SNU71
unreported in EBV(þ) gastric cancer previously, was evaluatedTo clarify if the EBV-associated mutations in AGS–EBV
also occurred in primary EBV(þ) gastric cancers, we per-
formed Sanger sequencing to compare the prevalence of
mutations in AKT2, CCNA1, TGFBR1, ACVR1C, and MAP3K4
between EBV(þ) and EBV(-) gastric cancer samples. These
genes were chosen for validation because they are func-
tionally important in human cancers15–25 and their EBV-
associated mutations were located within conserved
domains (Supplementary Figure 3). When compared with
EBV(-) gastric cancers, somatic mutations occurred signiﬁ-
cantly more frequently in EBV(þ) gastric cancers in AKT2
(38.2% vs 3%; P < .0001), CCNA1 (25% vs 4%; P ¼ .004),
MAP3K4 (20.8% vs 4%; P ¼ .013), and TGFBR1 (25% vs 8%;
P ¼ .029) (Figure 2B and Supplementary Figures 4–7).
Mutations in AKT2 Are Associated With
Reduced Survival Times of Patients With
EBV(þ) Gastric Cancer
We further evaluated the clinical implication of muta-
tions in the putative oncogene AKT2, which is the only gene
harboring 2 EBV-associated nonsynonymous mutations in
AGS–EBV cells, and mutation in which the most signiﬁcant
association with primary EBV(þ) gastric cancer was shown.
In the examined cohort of 34 EBV(þ) gastric cancers with
known follow-up data, the mutation frequency of AKT2 was
38.2% (13 of 34) (Supplementary Tables 9 and 10). Inter-
estingly, as shown in the Kaplan–Meier survival curves
(Figure 2C), EBV(þ) gastric cancer patients with an AKT2
mutation had signiﬁcantly reduced survival times (median,
3.27 y) than those with wild-type AKT2 (median, 4.72 y;
P ¼ .006, log-rank test).
Integrative Analysis of Epigenome and
Transcriptome Showed Genes Dysregulated by
Aberrant Methylation
To systematically identify genes directly dysregulated by
epigenetic alterations induced by EBV infection, tran-
scriptome of AGS–EBV, and AGS were analyzed integratively
with the epigenome data. Integrated analysis showed that
216 genes were hypermethylated and transcriptionally
down-regulated in AGS–EBV relative to AGS cells, whereas
only 46 genes were demethylated and transcriptionally
up-regulated in AGS–EBV (Figure 3A and Supplementary
Table 11). Six randomly selected genes (ACSS1, FAM3B,
IHH, NEK9, SLC7A8, and TRABD) were conﬁrmed to be down-
regulated signiﬁcantly in AGS–EBV compared with AGS and
AGS-hygro cells by semiquantitative RT-PCR and quantitative
RT-PCR (Figure 3B). Down-regulation of these genes could be
restored successfully in AGS–EBV cells by demethylation
treatment using 5-Aza-2’deoxycytidine (5-Aza) (Figure 3B).(þ) gastric cancer tissues. (A) Visualization of transcriptome
_007605). The vertical axis shows the sequencing depth of
horizontal axis denotes the location of the EBV genome, and
sing the Integrative Genomics Viewer (v2.1; Broad Institute,
els. Expression of the top 11 genes was evaluated further in
9, and YCCEL1) by RT-PCR. (C) Expression of 10 EBV genes,
in 13 primary EBV(þ) gastric cancer samples by RT-PCR.
Figure 2. EBV-associated host gene mutations in primary gastric cancers. (A) Chromosomal location of 45 AGS–EBV–speciﬁc
nonsynonymous SNVs covering 44 genes. The 5 genes screened further in primary gastric cancer samples are denoted. (Bi)
Comparison of mutation frequencies in EBV(þ) and EBV(-) gastric cancer samples by the chi-square or Fisher exact tests.
*Sample size later was increased for AKT2 genotype examination. (Bii) Schematic illustration of mutations found in AKT2.
Mutation sites found in EBV(þ) and EBV(-) gastric cancer samples are denoted with red arrows and black arrows in the upper
lanes and lower lanes, respectively. The mutation sites identiﬁed in AGS–EBV cells also are shown with blue arrows in the
upper lane. Nucleotide and amino acid changes are indicated for each mutation site. The frequencies (number of cases) of
each mutation are indicated by the height of the arrow. (C) Kaplan–Meier survival curves show that EBV(þ) gastric cancer
patients with mutated AKT2 had reduced survival times compared with patients with wild-type AKT2. This difference was
statistically signiﬁcant based on the log-rank test (P ¼ .006). GC, gastric cancer.
1354 Liang et al Gastroenterology Vol. 147, No. 6
BASIC
AND
TRANSLATIONAL
ATHigher methylation levels of these genes in AGS–EBV as
compared with AGS and AGS-hygro cells were conﬁrmed by
bisulﬁte genomic sequencing, and the methylation levels
were decreased successfully by 5-Aza treatment (Figure 3C).
We have shown that DNA methyltransferase 3b (DNMT3b)
was up-regulated in AGS–EBV compared with AGS cells.3
There were no differences in messenger RNA expression;
nuclear protein expression of DNMT1, DNMT3a, and
DNMT3b; and the activity of DNMT3b between uninfected
AGS and the vector-transfected, hygromycin-resistant AGS
cells (Supplementary Figure 8). These ﬁndings suggest thatEBV infection causes a genome-wide aberrant methylation
composed mainly of promoter/CpG island hypermethylation,
which directly lead to gene transcriptional down-regulation.Validation Conﬁrmed Genes Methylated
Preferentially in Primary EBV(þ) Gastric Cancers
To clarify if aberrant methylation caused by EBV infec-
tion in AGS–EBV cells also occurred in primary gastric
cancers, promoter methylation statuses of ACSS1, FAM3B,
IHH, and TRABD were examined in EBV(þ) and EBV(-)
Figure 3. Identiﬁcation and validation of aberrantly methylated genes involved in EBV-associated gastric cancer. (A) Dot plots
of genes of differential transcription and methylation between AGS and AGS–EBV cells shown by methylated DNA immu-
noprecipitation microarray chip and transcriptome sequencing, respectively. (B) Transcriptional down-regulation of the
selected genes in AGS–EBV and restoration by demethylation treatment using 5-Aza were shown. (C) Bisulﬁte genomic
sequencing conﬁrmed that selected candidates were methylated at signiﬁcantly higher levels in AGS–EBV cells than in AGS
cells, and could be demethylated by 5-Aza treatment. The location of CpG island and bisulﬁte genomic sequencing target
regions was shown for each gene, with black bars denoting the ﬁrst exons. TSS, transcription start site. (D) Comparison of
promoter methylation of 4 EBV-associated methylated genes in 20 EBV(þ) and 20 EBV(-) primary gastric cancers by bisulﬁte
genomic sequencing. Average methylation levels at each site for EBV(þ) and EBV(-) samples are shown. P values were ob-
tained by paired t tests. Knock-down of (Ei) IHH and (Fi) TRABD expression was performed by transfecting short hairpin RNAs
(shRNAs) speciﬁcally targeting 2 different regions of each gene in cells of high expression, AGS and GES-1, respectively.
Overexpression of (Eii) IHH and (Fii) TRABD in BGC823 cells was achieved by stable transfection of expression vectors. Cell
growth and colony formation ability were compared correspondingly.
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cantly higher methylation levels were observed in EBV(þ)
gastric cancers as compared with EBV(-) gastric cancers in
ACSS1 (12.6% vs 2.0%; P ¼ .004), FAM3B (44.6% vs 34.0%;
P ¼ .017), IHH (30.1% vs 0.0%; P ¼ .005), and TRABD
(20.9% vs 3.0%; P ¼ .000) (Figure 3D).
EBV-Associated Methylated Genes Possess
Tumor-Suppressive Potentials
We further investigated the function of 2 genes methyl-
ated in EBV(þ) gastric cancers (IHH andTRABD). Gene knock-
down or ectopic expression was obtained by stable trans-
fection of speciﬁc short hairpin RNA or open reading frame–
expressing vectors in cells with high or low endogenous
expression of the corresponding gene. Knock-down of IHH by
short hairpin RNA transfection in AGS cells signiﬁcantly
increased cell growth and colony formation ability compared
with the control cells, whereas overexpression of IHH in the
silenced cell line BGC823 signiﬁcantly inhibited cell growth
and colony formation (Figure 3E). Similarly, knock-down of
TRABD signiﬁcantly increased cell growth and the colony
formation ability of GES-1 cells, whereas overexpression of
TRABD in BGC823 cells signiﬁcantly inhibited cell growth and
colony formation (Figure 3F). These results show that IHH
and TRABD possess potential tumor-suppressive properties
and their down-regulation by hypermethylation may play
roles in EBV-associated gastric carcinogenesis.
Host Genetic and Epigenetic Alterations Caused
by EBV Infection Commonly Involve Five
Intercorrelated Cancer Pathways
To investigate the dysregulated pathways by EBV infec-
tion–induced host genomic and epigenomic changes, enrich-
ment analysis for Kyoto Encyclopedia of Genes and Genomes
pathways was conducted using 205 genes with genetic al-
terations and 262 genes with aberrant methylation-mediated
transcriptional changes, respectively (Figure 4A). Genetically
changed genes were found to be enriched in 13 pathways,
whereas epigenetically changed genes were enriched in 15
pathways (with4 genes involved in each pathway; adjusted
P < .05). Notably, hypermethylated genes were found to be
enriched in only 10 pathways (4 genes; P < .05). Eight
pathwayswere dysregulated signiﬁcantly by both genetic and
epigenetic changes. Interestingly, these 8 pathways also were
dysregulated signiﬁcantly by hypermethylation only
(Figure 4B and Supplementary Table 12). Because pathways
in cancer and metabolic pathways can be hit easily by
enrichment analysis, and all altered genes in the colorectal
cancer pathway are included in pathways in cancer, we paid
attention to the remaining 5 important affected pathways,
including axon guidance, focal adhesion, cytokine-cytokine
receptor interaction, MAPK signaling, and regulation of
actin cytoskeleton.
Diagrams showing genetically or epigenetically altered
genes in the 5 core pathways are shown in Figure 5.
Remarkably, these 5 pathways are intercorrelated. The
axon guidance pathway correlates with cytokine-cytokine
receptor interaction, regulation of actin cytoskeleton, andMAPK signaling pathways; focal adhesion also correlates
with cytokine-cytokine receptor interaction, regulation
of actin cytoskeleton, and MAPK signaling pathways
(Supplementary Figure 9). Importantly, the putative onco-
gene AKT2, mutation of which was found to be associated
with reduced survival times of patients with EBV(þ)
gastric cancer, is involved in 2 of the 5 core pathways
(focal adhesion and MAPK signaling) (Figure 5). Collec-
tively, axon guidance, focal adhesion, cytokine-cytokine
receptor interaction, MAPK signaling, and regulation of
actin cytoskeleton pathways are the core pathways dysre-
gulated during EBV-associated gastric carcinogenesis.AKT2 Was Activated by Mutation and
Participated in Dysregulating MAPK Signaling
We investigated the effects of AKT2 mutation on AKT2
activity through assessing AKT2 phosphorylation byWestern
blot and total AKT kinase activity by activity assays. Our re-
sults showed that the phosphorylated AKT2 (p-AKT2) level
was signiﬁcantly higher in AGS–EBV as compared with AGS,
and inmutant AKT2-transfected AGS than inwild-type AKT2-
transfected AGS cells (Figure 6A). In concordance with
enhanced p-AKT2, total AKT kinase activity was increased
signiﬁcantly in mutant AKT2-carrying AGS–EBV compared
with AGS, and in mutant AKT2-carrying AGS compared with
wild-type AKT2-overexpressed AGS (Figure 6A).
Activator protein-1 (AP-1) and extracellular signal–
regulated kinase (ERK) are pivotal mediators in MAPK
signaling involving AKT2. We evaluated the effects of AKT2
mutation on the activities of AP-1 and ERK by promoter
luciferase activity assays using promoter reporters con-
taining AP-1 and serum response element (SRE) binding
elements, respectively. Results showed that both AP-1 and
ERK activities were increased signiﬁcantly in mutant AKT2-
carrying cells compared with wild-type AKT2-carrying cells
(Figure 6B). To further conﬁrm the role of AKT2 mutation
on AP-1 and ERK activity, mutant and wild-type AKT2 were
expressed ectopically in the immortalized normal gastric
epithelial cell line GES-1 with low endogenous AKT2
expression. Again, a higher p-AKT2 level, increased total
AKT kinase activity, and promoted AP-1 and ERK activities
were detected in mutant AKT2-transfected GES-1 cells
compared with wild-type AKT2-transfected GES-1 cells
(Figure 6C and D). Moreover, mutant AKT2 was found to
promote cell growth and colony formation ability of GES-1
cells as compared with wild-type AKT2. These results
imply that AKT2 was activated by mutation and participated
in dysregulating MAPK signaling.Discussion
The AGS–EBV cell model, a gastric epithelial cell model
with stable EBV infection, has been applied successfully to
study the effect of EBV infection on host gene transcription
and methylation.3,8–10 This cell model also has facilitated
our integrative genome-wide scan for alterations in EBV-
associated gastric cancer in this study by comparison with
its parental AGS cells.
Figure 4. Pathways dysregulated by EBV-associated host genomic and epigenomic alterations. (A) Circos illustration of EBV-
associated epigenetic and genetic changes identiﬁed in AGS–EBV as compared with AGS cells. (B) Enrichment of Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathways with genetically or epigenetically changed genes. Pathways with 4 or
more genes involved and a P value less than .05 are considered as signiﬁcantly affected. Fc gamma R, Fc gamma receptor;
Jak-STAT, Janus kinase/signal transducers and activators of transcription; VEGF, vascular endothelial growth factor.
December 2014 EBV-Associated Alterations in Gastric Cancer 1357
BA
SI
C
AN
D
TR
AN
SL
AT
IO
NA
L
ATTranscriptome sequencing showed 9 well-documented
EBV genes (BARF0, BHRF1, BcLF1, BHRF1, BLLF1, BRLF1,
BZLF1, EBNA1, and LMP2A) in EBV-associated gastric can-
cer,14,26–29 and, notably, 71 EBV genes unreported in gastric
cancer. Importantly, the 10 top unreported EBV genes all
were veriﬁed in other EBV(þ) gastric cancer cells and pri-
mary EBV(þ) gastric cancer samples (Figure 1B and C). The
frequencies of these EBV genes in EBV(þ) gastric cancers all
were signiﬁcant except the one for the BKRF3 gene (7.7%)
when compared with those in EBV(-) gastric cancers (0%;
n ¼ 20, chi-square test). Expression of previously unre-
ported EBV genes may be involved in EBV-associated gastric
cancer. Expression of EBV genes with potential oncogenic
function has been reported in EBV-associated gastriccarcinogenesis, including BARF1,29 BHRF1,13,14 and RPMS1
(encoding BARTs microRNAs).30 Expression of the latent
gene LMP2A has been reported to up-regulate survivin,
contributing to the survival advantage of EBV-associated
gastric cancer cells,31 and activate cellular DNMT3b,
causing the genome-wide aberrant methylation of host
cells.3 EBV resides in the host cell nucleus as an episome
during latency infection and the EBV genome is too large
(approximately 170 kb) to be integrated into the host
genome. Therefore, EBV might induce host genetic and
epigenetic variants through executing its repertoire of gene
expression programs, subsequently contributing to the
unique pathobiology of virus-associated gastric cancer.
Identiﬁcation of the previously unreported EBV genes in
Figure 5. Diagram illustra-
tion of the 5 core pathways
commonly dysregulated by
epigenetic and genetic
changes. Genetically or
epigenetically altered
genes in the 5 core path-
ways are denoted with a
yellow background. Muta-
tion frequencies of AKT2,
TGFBR1, and MAP3K4
in primary EBV(þ) gastric
cancers are indicated.
ECM, extracellular matrix;
PIP3, phosphatidylinositol
3,4,5-trisphosphate. The
other abbreviations listed
are gene names.
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infection in contributing to this subtype of gastric
carcinogenesis.
By analyzing the epigenome data integratively with
transcriptome data in this study, we identiﬁed 216 genes
transcriptionally down-regulated by EBV-caused hyper-
methylation and 46 genes transcriptionally up-regulated by
demethylation. Genes with inconsistent changes in methyl-
ation and transcription might be the result of involvement
of other regulatory mechanisms such as microRNAs and
transcription factors.10,32 Further validation has conﬁrmed
that promoter methylation levels of ACSS1, FAM3B, IHH, and
TRABD were signiﬁcantly higher in primary EBV(þ) than in
EBV(-) gastric cancers, with tumor-suppressive potential
shown by gain-of-function and loss-of-function experimentsin vitro (Figure 3). Previous reports from us and others have
shown that promoter methylation of SSTR1, REC8, p14, p15,
p16, p73, APC, E-cadherin, and PTEN are associated with
EBV-associated gastric cancer.3,8,33–35 These results suggest
that EBV infection causes hypermethylation of a speciﬁc
group of genes, and silencing of these genes may favor
malignant transformation of gastric epithelial cells during
development of this unique subtype of gastric cancer.
Whole-genome sequencing of the AGS–EBV and AGS
cells identiﬁed EBV infection–associated genetic alterations
affecting 205 host genes. Among the 44 genes harboring
amino acid–changing mutations, we conﬁrmed that muta-
tions of AKT2, CCNA1, MAP3K4, and TGFBR1 were associated
signiﬁcantly with EBV(þ) gastric cancers (Figure 2B).
No mutations in these genes were detected in the
Figure 6. AKT2 was activated by mutation and functioned in dysregulating MAPK signaling. (A) Total and phosphorylated
AKT2 protein levels were assessed by Western blot. Total AKT kinase activity was evaluated by AKT kinase activity assay. (B)
Luciferase reporter assays indicated that the important MAPK signaling mediators (AP-1 and ERK) were both activated in
mutant AKT2-carrying cells as compared with wild-type AKT2-carrying cells. (C) After ectopic expression in GES-1 cells,
mutant AKT2 was phosphorylated at a higher level, and accompanied by increased total AKT kinase activity as compared with
wild-type AKT2. (D) Mutant AKT2 activated AP-1 and ERK signaling as compared with wild-type AKT2. (E) Mutant AKT2
promoted cell viability and colony formation ability as compared with wild-type AKT2. GAPDH, glyceraldehyde-3-phosphate
dehydrogenase.
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stomach samples (data not shown).
AKT2 is a putative oncogene encoding a protein that
participates in important cancer pathways such as MAPK
signaling. Mutation of AKT2 has been investigated in human
cancers,15,16 but not in EBV-associated gastric cancer. Cyclin
A1 (CCNA1) belongs to the cyclin family, and primarily
functions in the control of the germline meiotic cell cycle.
Previous studies have shown that CCNA1 play different
roles in virus-related and non–virus-related malig-
nancies.17–20 However, mutation of CCNA1 has never been
reported. CCNA1 mutations in EBV(þ) gastric cancer as
identiﬁed by us might suggest another mechanism of the
role of CCNA1 in human malignancies. Transforming growth
factor-b–receptor 1 (TGFBR1) is a serine/threonine protein
kinase and receptor for TGF-b. Mutations in TGFBR1 have
been found in skin and colorectum cancers.21,22 MAP3K4
functions as a major mediator of environmental stressors
that activate the p38 MAPK pathway,23 and its mutation has
been reported in endometrial cancer.24 Recognizing the
functional importance of these genes in human cancers,
mutations of these genes caused by EBV infection may
contribute at least in part to the pathogenesis of EBV-
associated gastric cancer.Figure 7. Study summary. EBV gene expression proﬁle, EBV
indentiﬁed in a cell model and validated further in primary EBV(
gene LMP2A expression activates DNMT3b and causes genom
were found to be enriched signiﬁcantly with genetically and
functional importance of selected methylated and mutated genFinally, 5 intercorrelated core pathways (axon guidance,
focal adhesion, cytokine-cytokine receptor interaction,
MAPK signaling, and regulation of actin cytoskeleton) were
found to be commonly enriched with genetically and
epigenetically changed genes caused by EBV infection. In
addition to the several epigenetically or genetically changed
up-stream and down-stream targets of focal adhesion ki-
nase in the focal adhesion pathway we identiﬁed (Figure 5),
focal adhesion kinase phosphorylation has been reported to
be increased by EBV infection and the subsequently
increased cell motility in AGS cells.36 This ﬁnding further
supports the importance of the focal adhesion pathway in
EBV-associated gastric cancer. Promoted anchorage-
independent growth of EBV-infected AGS in soft agar, a
hallmark phenotype of cellular transformation, has been
reported by others.10 We also have observed a more un-
differentiated morphology of AGS–EBV as compared with
AGS when both cells were cultured in the same F12
medium (not shown). These phenotype changes might be
associated with the focal adhesion pathway. Although the
other 4 pathways have never been reported in EBV-
associated cancer, 3 of them (cytokine-cytokine receptor
interaction, MAPK signaling, and regulation of actin cyto-
skeleton) have been reported to be affected by EBV-associated host genomic and epigenomic alterations were
þ) gastric cancers. Our previous study showed that EBV viral
e-wide aberrant methylation in AGS–EBV. Five core pathways
epigenetically altered genes caused by EBV infection. The
es as well as the pathway was shown.
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cells,37,38 suggesting common dysregulation of these path-
ways by EBV infection in different cell types during disease
initiation. Dysregulation of the 5 core pathways through
both genetic and epigenetic modulation of host genes by
EBV infection may play important roles during this subtype
of gastric carcinogenesis.
Among all the host genes altered by EBV infection iden-
tiﬁed in this study, AKT2 is the most notable one. AKT2 was
the only gene (of 44 genes) harboring 2 nonsynonymous
point mutations identiﬁed in AGS–EBV cells. AKT2 mutation
was also the highest in frequency and associated most
signiﬁcantly with primary EBV(þ) gastric cancer as
comparedwith EBV(-) gastric cancer. Importantly, we further
conﬁrmed that mutations in AKT2 were associated with
reduced survival in EBV(þ) gastric cancer patients. Inter-
estingly, AKT2 is also the only gene involved in 2 of the 5 core
pathways (focal adhesion and MAPK signaling). The mutant
form of AKT2 identiﬁed in AGS–EBV possessed higher kinase
activity, increased activities of the important mediators of the
MAPK signaling pathway (AP-1 and ERK), and exerted a
promoting effect on cell growth as compared with wild-type
AKT2 (Figure 6). All these ﬁndings emphasize the importance
of AKT2 in connection with EBV(þ) gastric cancer.
In summary, as shown in Figure 7, this study systemati-
cally showed the EBV-associated genomic and epigenomic
alterations in gastric cancer. Expression of EBV genes in
gastric cancer was shown by transcriptome analysis of the
EBV-infected cell model and further conﬁrmed in EBV(þ)
primary gastric cancers. Whole-genome sequencing showed
EBV-associated host mutations in genes such as AKT2, CCNA1,
MAP3K4, and TGFBR1, and mutations in AKT2 are associated
with reduced survival times of patients with EBV(þ) gastric
cancer. Epigenome analysis uncovered hypermethylation of
genes including ACSS1, IHH, FAM3B, and TRABD through EBV
infection. Five core pathways were shown to be dysregulated
by EBV-associated host genomic and epigenomic aberrations
in gastric cancer. Moreover, the functional importance of
selected genes (IHH, TRABD, and AKT2) and pathway (MAPK)
were shown further. These ﬁndings provide a systematic
view of EBV-associated host genomic and epigenomic ab-
normalities and signaling networks that may govern the
pathogenesis of EBV-associated gastric cancer.Supplementary Material
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Supplementary Materials and Methods
EBV Strain and Establishment of the
EBV-Infected Cell Line AGS-EBV
The 170-kb EBV genome of the B95.8 strain was cloned
onto the modiﬁed 6.5-kb pMBO131 F factor plasmid, which
was added with the genes for hygromycin-resistance and
green ﬂuorescence protein, using a homologous recombi-
nation strategy by Delecluse et al.1 The resulting modiﬁed
EBV strain, the B95.8 co-integrate that encompasses the
genes of hygromycin resistance and green ﬂuorescence
protein, was used to establish the epithelial cell model with
stable EBV infection (AGS–EBV) as follows. 293 cell clones
producing infectious virions of the modiﬁed EBV strain was
established to serve as the EBV shuttle system.1 The
modiﬁed EBV-carrying Burkitt lymphoma Akata cell line
was created by incubating Akata cells with the superna-
tants from induced 293 cell clones producing infectious
virions.2 The AGS–EBV cell line (a generous gift from Pro-
fessor Shannon C. Kenney, Departments of Oncology and
Medicine, McArdle Laboratory for Cancer Research, Uni-
versity of Wisconsin School of Medicine and Public Health,
Madison, WI) was obtained by co-culturing AGS cells with
the B95.8/F factor-carrying Akata cells and selecting by
hygromycin.
Whole-Genome Sequencing
Genomic DNA from AGS–EBV and AGS cells were frag-
mented to an average size of 300 nucleotides or 500 nucle-
otides, respectively. Standard Illumina protocols and Illumina
paired-end adapters then were used for library preparation.
DNA library sequencing then was performed on an Illumina
HiSeq 2000 (San Diego, CA) as per the manufacturer’s
instructions.
Transcriptome Sequencing
Total RNA isolated from AGS–EBV and AGS cells were
subjected to transcriptome sequencing. Poly-A containing
messenger RNA puriﬁcation, double-stranded complemen-
tary DNA synthesis, end repair, 3’ end adenylation, adapter
ligation, and enrichment of DNA fragments for RNA-seq li-
brary construction were performed using the reagents pro-
vided in the Illumina TruSeq RNA Sample Preparation Kit.
RNA-seq library sequencing then was performed on an
Illumina HiSeq 2000 as per the manufacturer’s instructions.
The transcriptome pair-ended sequencing reads were ﬁrst
ﬁltered to remove low-quality reads or reads with adapters.
The remaining qualiﬁed reads were used for further analysis.
EBV Gene Expression Analysis Using
Transcriptome Data
For analysis of EBV genes, the reads unmapped to human
genome 19 (hg19) refMrna.fa ﬁrst were aligned to the whole
human hg19 genome. The remaining unmapped reads then
were aligned to the EBV genome to analyze EBV gene
expression. The RPKM expression level for each EBV gene
was calculated as described.3 We then used the Integrative
Genomics Viewer for visualization of the EBV expression
results. In total, 154.09 Mb sequence reads of the AGS–EBV
transcriptome were mapped to the EBV genome.
Validation of EBV Gene Expression in Gastric
Cancer Cell Lines and in Primary EBV(þ) Gastric
Cancer Samples
Expression of selected EBV genes was validated in AGS,
AGS–EBV, and 2 gastric cancer cell lines with natural EBV
infection (SNU719 and YCCEL1) by RT-PCR. Expression of
these genes also was examined in 13 primary EBV(þ)
gastric cancer samples. The primers used are listed in
Supplementary Table 1.
Human and EBV Genome Alignment
The whole-genome pair-ended sequencing reads of low
quality or containing adapters ﬁrst were removed. Qualiﬁed
reads then were aligned to the human reference genome
hg19 by a BWA aligner,4 allowing no more than 1 gap
located more than 15 bp from either end of each mapped
read. No more than 2 mismatches were allowed between
the reference and the read. PCR duplicates also were
removed using SAMtools.5 The mapped reads were ﬁltered,
and the remaining unmapped reads to hg19 then were
aligned to the EBV reference genome (NC_007605) using
the same methods.
EBV-Associated SNVs Calling
Somatic single-site mutations were identiﬁed by
SOAPsnv (http://soap.genomics.org.cn/SOAPsnv.html). We
set the following criteria to call EBV-associated SNVs: (1)
read depth of 7 or more in both AGS and AGS–EBV samples;
(2) mutant allele is not called from repeated reads; (3)
mutated allele of 20% or more in the AGS–EBV sample and
2% or less in the AGS sample; (4) mutant allele frequency is
signiﬁcantly higher in AGS–EBV than in AGS (Fisher exact
test, P < .01); (5) reads supporting mutated alleles are not
the results of sequencing error (binomial test, f ¼ 0.1, P >
.01); (6) sequencing scores of mutated alleles are not
signiﬁcantly lower in AGS–EBV than in AGS cells (Wilcoxon
rank sum test, P > .01); and (7) mutant alleles are not
located less than 10 bp from the 5’ or 3’ ends of reads
(Fisher exact test, P > .01). Resulting EBV-associated SNVs
then were compared with single-nucleotide polymorphisms
documented in dbSNP132 (http://hgdownload.soe.ucsc.
edu/goldenPath/hg19/database/snp132.txt.gz) and the
1000 Genomes project6 to identify novel SNVs. Functional
annotation was performed using an optimized program
based on PolyPhen embedded in SOAPsnv. SNVs also were
compared with mutations documented in the Catalogue of
Somatic Mutations in Cancer (www.cosmic-software.com/
download.php).
EBV-Associated Indels Calling
The SomaticIndelDetector, a program in GATK, was
applied for somatic indels calling.7 A putative indel will be
discarded if the following occurs: (1) the depth at the site in
AGS or AGS–EBV samples is less than 8; (2) the somatic
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indel frequency is less than 20%; (3) the maximal average
mismatches per somatic indel-supporting reads of AGS–EBV
is greater than 3; and (4) the minimal average mapping
qualities of somatic indel-supporting reads of AGS–EBV are
less than 10. Resulting EBV-associated indels then were
compared with indels documented in dbSNP132 to identify
novel indels. Functional annotation was performed using
ANNOVOR.8
EBV-Associated SVs Calling
By using the BWA alignment result of AGS–EBV against
AGS in BAM format, SVs were detected by CREST software,
which uses soft-clipped reads for SV detection.9 We used
the somatic module to identify SVs. In total, 48 SV events
were found to appear speciﬁcally in AGS–EBV as compared
with AGS. Sequences disrupted by SVs were annotated
manually according to the refGene database downloaded
from UCSC (http://hgdownload.soe.ucsc.edu/goldenPath/
hg19/database/refGene.txt.gz).
Validation of Mutations, Indels, and SVs
Putative AGS–EBV–speciﬁc mutations, indels, and SVs
identiﬁed by whole-genome sequencing were validated by
PCR and conventional Sanger sequencing of both cell lines
and primary human tissue samples. The primers used are
listed in Supplementary Table 1. We evaluated mutation
frequencies of selected genes in DNAs from 24 EBV(þ) and
100 EBV(-) gastric cancer samples, as well as the corre-
sponding nontumor stomach tissues. Sample size was
increased to 34 EBV(þ) gastric cancer samples, with follow-
up data in the evaluation of the correlation between AKT2
mutation status and survival.
Differential Gene Expression Analysis Using
Transcriptome Data
The RPKM expression levels for each gene in AGS–EBV
and AGS samples were calculated as described.3 For each
gene, the probability of the gene being expressed equally in
2 samples was calculated using the algorithm introduced by
Audic and Claverie.10 Because thousands of hypotheses are
tested simultaneously in this analysis, correction for false-
positive (type I) and false-negative (type II) errors was
performed using the False Discovery Rate (FDR) method.
Genes that ﬁt the following criteria were considered
differentially expressed genes, as follows: (1) RPKM greater
than 0.5 and read counts of 10 or higher in at least 1 cell,
and (2) both FDR and a P value less than .001.
Genome-Wide Proﬁling of EBV-Driven
DNA Methylation
DNA methylation proﬁling of AGS–EBV and AGS cells
was performed using methylated DNA immunoprecipitation
coupled with hybridization on a high-resolution microarray.
We used the Agilent custom Human CpG island Microarray
and Human Promoter array, which is 1M feature covering
approximately 17,000 reﬁned human genes (Agilent Tech-
nologies, Santa Clara, CA). The experiment procedures are
as previously described.11
Integrative Analysis of Epigenome and
Transcriptome Data
Targets of differential methylation (fold-change log ratio
> 1; P < .05) between AGS–EBV and AGS were included for
correlative analysis with differentially expressed genes.
Genes transcriptionally down-regulated with CpG hyper-
methylation and those transcriptionally up-regulated with
demethylation were considered as candidates that were
dysregulated by epigenetic change.
Validation of Genes Dysregulated by
Epigenetic Change
Transcription and methylation levels of randomly
selected candidates were examined by RT-PCR/quantitative
RT-PCR and bisulﬁte genomic sequencing, respectively.
Demethylation treatment of AGS–EBV cells using 5-Aza, as
well as RT-PCR and bisulﬁte genomic sequencing, were
performed as described previously.11 Quantitative RT-PCR
was performed on a LightCycler 480 real-time PCR system
(Roche Applied Science, Indianapolis, IN) using the Light-
Cycler 480 SYBR Green I Master (Roche) following the
manufacturer’s instructions. CpG islands were predicted
using the CpG island searcher (http://cpgislands.usc.edu/)
using default parameters except for SLC7A8 (length,
300 bp). Bisulﬁte genomic sequencing primers were
designed using MethPrimer (http://www.urogene.org/cgi-
bin/methprimer/methprimer.cgi). The methylation level at
each CpG site was calculated as the height ratio of cytidine/
(cytidine þ thymine). Promoter methylation of selected
genes also was examined in 20 EBV(þ) and 20 EBV(-)
gastric cancer samples by bisulﬁte genomic sequencing.
Messenger RNA expression of DNMT1, DNMT3a, and
DNMT3b was evaluated by quantitative RT-PCR. The
primers used are listed in Supplementary Table 1.
Enrichment Analysis of Kyoto Encyclopedia of
Genes and Genomes Pathways
Genes dysregulated by epigenetic changes (216 hyper-
methylated and 46 demethylated) and those altered
genetically (205 genes affected by SNV, indel, or SV) were
included in the Kyoto Encyclopedia of Genes and Genomes
pathway enrichment analysis using the Gene Set Analysis
Toolkit V2 (http://bioinfo.vanderbilt.edu/webgestalt/). The
hypergeometric test statistical method and the BH multiple
test adjustment method were used. All genes from human
beings were used as reference. Pathways with at least 4
genes and adjusted P values of less than .05 were consid-
ered signiﬁcantly enriched.
Cell Culture
The YCCEL1 cell line with natural EBV infection was a
gift from the Department of Internal Medicine at Yonsei
University College of Medicine, and cultured as previously
described.12 The gastric cancer cell line AGS was purchased
from the American Type Culture Collection (Manassas, VA).
The SNU719 cell line with natural EBV infection was pur-
chased from the Korean Cell Line Bank (Seoul, Korea). The
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gastric cancer cell line BGC823 and the immortalized hu-
man gastric epithelial cell line GES-1 were gifts from
Oncology Hospital (Beijing University, China). AGS, SNU719,
BGC, and GES-1 cells were maintained in RPMI-1640 culture
medium supplemented with 10% fetal bovine serum.
AGS–EBV cells were maintained in Ham’s F-12 medium with
10% fetal bovine serum and 100 ng/mL hygromycin. AGS-
hygro cells with stable transfection of empty vectors car-
rying the hygromycin-resistance gene, which were under
hygromycin selection for more than 3 months, were main-
tained in the same condition as AGS–EBV. AGS cells also
were maintained in Ham’s F-12 medium with 10% fetal
bovine serum for at least 1 month before performing AKT
kinase activity and luciferase reporter assays in comparison
with AGS–EBV cells.
Immunoﬂuorescence
AGS and AGS–EBV cells grown on coverslips were ﬁxed
with 3% (vol/vol) paraformaldehyde at 4C overnight. Cells
were incubated with 3% bovine serum albumin at room
temperature for 30 minutes and then with primary mouse
monoclonal antibody against BRLF1 (1:100) (11-008; Argene,
Verniolle, France) at 4C overnight. Cells then were probed
with Alexa Fluor–488 goat anti-mouse secondary antibody
(1:500; Invitrogen, Carlsbad, CA) and incubated at room
temperature for another 2 hours. Nuclear DNA was stained
with 40,6-diamidino-2-phenylindole (Molecular Probes,
Eugene, OR). Cells then were mounted and observed under a
ﬂuorescent microscope (TS100-F; Nikon, Kanagawa, Japan).
Construction and Transfection of
Expression Vectors
The pcDNA3.1 expression vectors containing the
full-length open reading frames of human AKT2 (both wild-
type and mutant ampliﬁed directly from AGS–EBV comple-
mentary DNA), IHH, and TRABD genes were constructed. The
sequences of the constructs were conﬁrmed by sequencing.
The immortalized gastric cell line GES-1 with low AKT2
expression was transfected with wild-type or mutant AKT2
expression vectors; the gastric cancer cell line BGC823 with
low IHH and TRABD expression was transfected with IHH or
TRABD expression vectors using Lipofectamine 2000 (Invi-
trogen), cells were transfected with empty pcDNA3.1 vectors
as control. Stably transfected cells were established under
selection with neomycin (G418) (Invitrogen).
Gene Knockdown
A set of vectors carrying short hairpin RNAs (shRNA)
against IHH and RABD was purchased from Origene
(Rockville, MD). The IHH-expressing AGS cells and TRABD-
expressing GES-1 cells were transfected accordingly, with
vectors carrying scrambled sequence as control. Knock-
down efﬁciency was evaluated 3 days after transfection by
real-time quantitative RT-PCR. The two shRNA vectors with
highest knockdown efﬁciency were used further to establish
stable knockdown cells under selection with puromycin
(Invitrogen) for colony formation assay and cell viability
assay.
Western Blotting
Protein was isolated from cultured cells using Cyto-
Buster Protein Extraction Reagent (Merck Chemicals,
Nottingham, UK) with a protease inhibitor cocktail.
Phosphatase inhibitor also was used when the proteins
were for phosphorylation detection. Nuclear proteins
were extracted using the NE-PER Nuclear Extraction Re-
agents (Pierce Biotechnology, Rockford, IL). Protein con-
centration then was measured by the Bradford DC protein
assay method (Bio-Rad, Hercules, CA). After separation by
sodium dodecyl sulfate–polyacrylamide gel electropho-
resis, proteins then were transferred to an equilibrated
polyvinylidene diﬂuoride membrane (Amersham Bio-
sciences, Buckinghamshire, UK). The primary antibodies
used included Akt2-speciﬁc phospho-Akt2 (Ser474)
(D3H2) and Akt2 (5B5) rabbit monoclonal antibodies
(Cell Signaling, Danvers, MA), anti-His (Abcam, Cambridge,
UK), anti–glyceraldehyde-3-phosphate dehydrogenase (Cell
Signaling), anti-DNMT1 (Cell Signaling), anti-DNMT3a (Cell
Signaling), anti-DNMT3b (Abcam), and anti–lamin A/C
(Transduction Laboratories, Lexington, KY).
DNMT3b Activity Assay
Activity of DNMT3b was measured using the EpiSeeker
DNMT3b assay kit (Abcam) according to the manufacturer’s
instructions. Ten micrograms of fresh nuclear protein from
cells were used in each test. The experiments were con-
ducted 3 times in triplicate.
AKT Kinase Activity Assay
Fresh proteins were prepared from cultured cells using
the CytoBuster Protein Extraction Reagent (Merck Chem-
icals), without addition of protease/phosphatase inhibitors.
The total AKT kinase activity then was evaluated using the
AKT kinase activity kit (Enzo Life Sciences, Farmingdale, NY).
Fifty micrograms of total protein from cells were used in each
test, with 10 ng of active protein kinase B included as positive
control.
Colony Formation Assay
Cells with stable overexpression or knockdown of target
genes were plated in 6-well plates (w2  103/well). After
culturing for 10–15 days, cells were ﬁxed with 70% ethanol
and stained with crystal violet solution. Colonies with more
than 50 cells per colony were counted. All experiments
were conducted 3 times in triplicate.
Cell Growth Assay
Cell growth curves of stably transfected cells were
monitored in real time on an xCELLigence System (Roche
Applied Science). The experiments were conducted in 3
independent experiments in triplicate and the results are
shown as the means ± SD.
Dual-Luciferase Reporter Assay
To assess the activity of the MAPK signaling pathway,
luciferase reporters for 2 important effectors, including
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AP1-luc (7  AP1 binding sites) and SRE-luc (5  SRE
binding elements) (0.1 mg/well), were cotransfected with
pRL-cytomegalovirus vector (2.5 ng/well) into AGS and
AGS–EBV cells in 24-well plates using Lipofectamine
2000 (Invitrogen). Cells were harvested 48 hours after
transfection and luciferase activities were analyzed by the
dual-luciferase reporter assay system according to the
manufacturer’s instructions (Promega, Madison, WI).
Statistical Analysis
All measurements or variables are shown as means ±
SD. The chi-square or the Fisher exact tests were used for
comparison of EBV status and distributions of gene muta-
tion. Overall survival in relation to mutation status was
evaluated by the Kaplan–Meier survival curve and the log-
rank test. Mann–Whitney U tests were performed to
compare the variables between 2 groups in colony forma-
tion and luciferase reporter assays. The difference in cell
growth between the 2 groups was determined by repeated-
measures analysis of variance. All statistical tests were
performed using Graphpad Prism 5.0 (Graphpad Software,
Inc, San Diego, CA), and a 2-tailed P value of less than .05
was considered statistically signiﬁcant.
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